Asset Management
Build Your Comparison
Side-by-side financial analysisStock Comparison
FHI vs IVZ
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
FHI vs IVZ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Asset Management | Asset Management |
| Market Cap | $4.49B | $12.50B |
| Revenue (TTM) | $1.86B | $6.59B |
| Net Income (TTM) | $399M | $-243M |
| Gross Margin | 51.5% | 50.7% |
| Operating Margin | 27.4% | -9.7% |
| Forward P/E | 11.6x | 10.9x |
| Total Debt | $457M | $10.12B |
| Cash & Equiv. | $584M | $1.98B |
FHI vs IVZ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Federated Hermes, I… (FHI) | 100 | 249.2 | +149.2% |
| Invesco Ltd. (IVZ) | 100 | 261.5 | +161.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FHI vs IVZ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FHI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 11.0%, EPS growth 58.8%
- 144.4% 10Y total return vs IVZ's 30.3%
- Lower volatility, beta 0.70, Low D/E 36.2%, current ratio 41.26x
IVZ is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 4 yrs, beta 1.61, yield 3.0%
- Beta 1.61, yield 3.0%, current ratio 43.01x
- Lower P/E (10.9x vs 11.6x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.0% NII/revenue growth vs IVZ's 5.1% | |
| Value | Lower P/E (10.9x vs 11.6x) | |
| Quality / Margins | Efficiency ratio 0.4% vs IVZ's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.70 vs IVZ's 1.61, lower leverage | |
| Dividends | 3.0% yield, 4-year raise streak, vs FHI's 2.4% | |
| Momentum (1Y) | +96.9% vs FHI's +43.1% | |
| Efficiency (ROA) | Efficiency ratio 0.4% vs IVZ's 0.5% |
FHI vs IVZ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FHI vs IVZ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
FHI leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
IVZ is the larger business by revenue, generating $6.6B annually — 3.5x FHI's $1.9B. FHI is the more profitable business, keeping 21.4% of every revenue dollar as net income compared to IVZ's -3.7%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.9B | $6.6B |
| EBITDAEarnings before interest/tax | $527M | $1.2B |
| Net IncomeAfter-tax profit | $399M | -$243M |
| Free Cash FlowCash after capex | $307M | $1.9B |
| Gross MarginGross profit ÷ Revenue | +51.5% | +50.7% |
| Operating MarginEBIT ÷ Revenue | +27.4% | -9.7% |
| Net MarginNet income ÷ Revenue | +21.4% | -3.7% |
| FCF MarginFCF ÷ Revenue | +16.5% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +1.6% | +34.2% |
Valuation Metrics
IVZ leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, FHI's 7.8x EV/EBITDA is more attractive than IVZ's 16.8x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $4.5B | $12.5B |
| Enterprise ValueMkt cap + debt − cash | $4.4B | $20.6B |
| Trailing P/EPrice ÷ TTM EPS | 11.51x | -17.58x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.56x | 10.91x |
| PEG RatioP/E ÷ EPS growth rate | 1.19x | — |
| EV / EBITDAEnterprise value multiple | 7.82x | 16.82x |
| Price / SalesMarket cap ÷ Revenue | 2.48x | 1.96x |
| Price / BookPrice ÷ Book value/share | 3.51x | 0.98x |
| Price / FCFMarket cap ÷ FCF | 15.23x | 8.68x |
Profitability & Efficiency
FHI leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
FHI delivers a 29.5% return on equity — every $100 of shareholder capital generates $30 in annual profit, vs $-2 for IVZ. FHI carries lower financial leverage with a 0.36x debt-to-equity ratio, signaling a more conservative balance sheet compared to IVZ's 0.78x. On the Piotroski fundamental quality scale (0–9), FHI scores 8/9 vs IVZ's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +29.5% | -1.7% |
| ROA (TTM)Return on assets | +18.2% | -0.9% |
| ROICReturn on invested capital | +24.1% | -2.3% |
| ROCEReturn on capital employed | +26.3% | -2.6% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 6 |
| Debt / EquityFinancial leverage | 0.36x | 0.78x |
| Net DebtTotal debt minus cash | -$127M | $8.1B |
| Cash & Equiv.Liquid assets | $584M | $2.0B |
| Total DebtShort + long-term debt | $457M | $10.1B |
| Interest CoverageEBIT ÷ Interest expense | 44.07x | -6.19x |
Total Returns (Dividends Reinvested)
Evenly matched — FHI and IVZ each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FHI five years ago would be worth $20,177 today (with dividends reinvested), compared to $12,217 for IVZ. Over the past 12 months, IVZ leads with a +96.9% total return vs FHI's +43.1%. The 3-year compound annual growth rate (CAGR) favors IVZ at 22.8% vs FHI's 19.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +14.2% | +6.0% |
| 1-Year ReturnPast 12 months | +43.1% | +96.9% |
| 3-Year ReturnCumulative with dividends | +69.2% | +85.1% |
| 5-Year ReturnCumulative with dividends | +101.8% | +22.2% |
| 10-Year ReturnCumulative with dividends | +144.4% | +30.3% |
| CAGR (3Y)Annualised 3-year return | +19.2% | +22.8% |
Risk & Volatility
FHI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FHI is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than IVZ's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FHI currently trades 98.7% from its 52-week high vs IVZ's 94.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.61x |
| 52-Week HighHighest price in past year | $59.83 | $29.82 |
| 52-Week LowLowest price in past year | $41.71 | $14.48 |
| % of 52W HighCurrent price vs 52-week peak | +98.7% | +94.4% |
| RSI (14)Momentum oscillator 0–100 | 67.2 | 59.2 |
| Avg Volume (50D)Average daily shares traded | 734K | 4.3M |
Analyst Outlook
IVZ leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates FHI as "Hold" and IVZ as "Hold". Consensus price targets imply 6.8% upside for IVZ (target: $30) vs -2.7% for FHI (target: $58). For income investors, IVZ offers the higher dividend yield at 2.96% vs FHI's 2.36%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $57.50 | $30.06 |
| # AnalystsCovering analysts | 21 | 28 |
| Dividend YieldAnnual dividend ÷ price | +2.4% | +3.0% |
| Dividend StreakConsecutive years of raises | 3 | 4 |
| Dividend / ShareAnnual DPS | $1.40 | $0.83 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.9% | +14.9% |
FHI leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IVZ leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
FHI vs IVZ: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is FHI or IVZ a better buy right now?
For growth investors, Federated Hermes, Inc.
(FHI) is the stronger pick with 11. 0% revenue growth year-over-year, versus 5. 1% for Invesco Ltd. (IVZ). Federated Hermes, Inc. (FHI) offers the better valuation at 11. 5x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate Federated Hermes, Inc. (FHI) a "Hold" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FHI or IVZ?
On forward P/E, Invesco Ltd.
is actually cheaper at 10. 9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — FHI or IVZ?
Over the past 5 years, Federated Hermes, Inc.
(FHI) delivered a total return of +101. 8%, compared to +22. 2% for Invesco Ltd. (IVZ). Over 10 years, the gap is even starker: FHI returned +144. 4% versus IVZ's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FHI or IVZ?
By beta (market sensitivity over 5 years), Federated Hermes, Inc.
(FHI) is the lower-risk stock at 0. 70β versus Invesco Ltd. 's 1. 61β — meaning IVZ is approximately 131% more volatile than FHI relative to the S&P 500. On balance sheet safety, Federated Hermes, Inc. (FHI) carries a lower debt/equity ratio of 36% versus 78% for Invesco Ltd. — giving it more financial flexibility in a downturn.
05Which is growing faster — FHI or IVZ?
By revenue growth (latest reported year), Federated Hermes, Inc.
(FHI) is pulling ahead at 11. 0% versus 5. 1% for Invesco Ltd. (IVZ). On earnings-per-share growth, the picture is similar: Federated Hermes, Inc. grew EPS 58. 8% year-over-year, compared to -235. 6% for Invesco Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FHI or IVZ?
Federated Hermes, Inc.
(FHI) is the more profitable company, earning 22. 3% net margin versus -4. 4% for Invesco Ltd. — meaning it keeps 22. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FHI leads at 29. 5% versus -10. 9% for IVZ. At the gross margin level — before operating expenses — FHI leads at 73. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FHI or IVZ more undervalued right now?
On forward earnings alone, Invesco Ltd.
(IVZ) trades at 10. 9x forward P/E versus 11. 6x for Federated Hermes, Inc. — 0. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVZ: 6. 8% to $30. 06.
08Which pays a better dividend — FHI or IVZ?
All stocks in this comparison pay dividends.
Invesco Ltd. (IVZ) offers the highest yield at 3. 0%, versus 2. 4% for Federated Hermes, Inc. (FHI).
09Is FHI or IVZ better for a retirement portfolio?
For long-horizon retirement investors, Federated Hermes, Inc.
(FHI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), 2. 4% yield, +144. 4% 10Y return). Invesco Ltd. (IVZ) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FHI: +144. 4%, IVZ: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FHI and IVZ?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FHI is a small-cap deep-value stock; IVZ is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.